Skip to main content
AMRX logo

Amneal Pharmaceuticals, Inc. (AMRX) Stock: Price, Forecast & Analyst Target

Amneal Pharmaceuticals, Inc. (AMRX) — MoonshotScore 68/100 (Strong band), calculated Nov 22, 2026. Price $21.12 (-1.26%), as of the Nov 20, 2026 trading session; market cap $7.36B. Expected results Feb 26, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 46.76× (market value Nov 17, 2026; cash Sep 30, 2026) · expected results Feb 26, 2027

$21.12 −$0.27 (-1.26%) Market Cap $7.36B

Amneal Pharmaceuticals, Inc. · AMRX · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-13: Amneal manufactures generic and branded pharmaceuticals across divisions serving wholesalers, specialty channels, and the government. A turnaround from near-break-even to robust profitability in recent quarters raises a central question: can the improvement hold despite mounting debt?

Price as of Nov 20, 2026

Key Statistics

68 of 100

MoonshotScore v2 · Amneal Pharmaceuticals (AMRX)

Strong
Business Quality Elite (84)
Financial Safety Fragile (18)
Valuation Full (43)
Growth Durability Fading (38)
Momentum Surging (98)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • Altman Z 1.96 · Piotroski F 5
  • ROE 70.0% · ROA 7.5% · current ratio 1.87

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AMRX (58 recorded, newest six shown)
RecordedScoreBand
71Strong
69Strong
69Strong
66Strong
66Strong
66Strong

The score moved from 66 in the stored Nov 21, 2026 snapshot to 68 in the current publication computed Nov 22, 2026 (+2); the largest pillar moves were Momentum +2. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$21.12
Change on the day-1.26%
52-week range$11.39–$22.07
Market capitalisation$7.36B
Price / earnings (trailing)49.12
Shares traded on the day1.67M
Beta (volatility vs the S&P 500)1.25

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $9.92, high $22, latest $21. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $22 $9.92 high $22 Feb 27, 2026 · Earnings results · reported above the recorded estimate · close $141May 7, 2026 · Earnings results · reported above the recorded estimate · close $132Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $183Nov 3, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $204Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $205 Oct 17, 2025 Nov 20, 2026 · $21 $9.92Oct 17, 2025$11Oct 31, 2025$12Nov 14, 2025$13Nov 28, 2025$12Dec 12, 2025$13Dec 26, 2025$13Jan 9, 2026$13Jan 23, 2026$15Feb 6, 2026$15Feb 20, 2026$13Mar 6, 2026$12Mar 20, 2026$12Apr 2, 2026$14Apr 17, 2026$13May 1, 2026$12May 15, 2026$13May 29, 2026$16Jun 12, 2026$17Jun 26, 2026$17Jul 10, 2026$18Jul 24, 2026$18Aug 7, 2026$18Aug 21, 2026$17Sep 4, 2026$19Sep 18, 2026$20Oct 2, 2026$19Oct 16, 2026$22Oct 30, 2026$21Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • On other two strengths, 60 mg and 90 mg, our post-approval supplement is ready, and we will be filing both the strengths in this quarter and expect the launch in the second half of next year.

    Chintu Patel · Statement from

  • We expect to launch in second half next year, towards late.

    Chirag Patel · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Amneal Pharmaceuticals (AMRX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Strong
Gross Margin Moderate

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Amneal Pharmaceuticals (AMRX), and what does it report?

Short answer · as of

Generics are commodity sales through wholesale channels where Amneal competes on manufacturing scale and cost.

But Specialty products—Rytary for Parkinson's, Unithroid for hypothyroidism—command premium pricing where brand and efficacy matter more than cost. AvKARE extends into long-term government contracts, creating a stickier revenue base. The income statement reflects this mix: gross margin expanded despite flat revenue, suggesting product mix favoring branded and contract sales.

2 · Latest results

What do the latest results show for Amneal Pharmaceuticals (AMRX)?

Recent quarters accelerated earnings per share and expanded operating margins substantially. The mechanism appears to be volume recovery in Generics following supply-chain normalization and a full period of contribution from prior Specialty acquisitions. AvKARE maintained steady contract revenues. The pace of improvement suggests demand tailwinds, though management guidance restraint signals caution about durability.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$862.68M Sep 30, 2026
Latest quarter · R&D
$68.37M Sep 30, 2026
Latest quarter · SG&A
$139.65M Sep 30, 2026
Latest quarter · FMP standardized operating result
$95.42M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$862.68M$68.37M$139.65M$95.42M
Jun 30, 2026$796.20M$41.10M$148.72M$145.98M
Mar 31, 2026$722.52M$38.38M$138.86M$142.87M
Dec 31, 2025$814.32M$34.82M$146.46M$114.50M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$862.68M Nov 3, 2026
Latest report · revenue estimate
$817.77M Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$862.68M$817.77M$0.2600$0.2374
Jul 30, 2026$796.20M$768.21M$0.3000$0.2225
May 7, 2026$722.52M$719.66M$0.2700$0.1700
Feb 27, 2026$814.32M$807.35M$0.2100$0.1800
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$785M$2M$0.01 (diluted)
Q4 FY2025$814M$35M$0.11 (diluted)
Q1 FY2026$723M$62M$0.19 (diluted)
Q2 FY2026$796M$58M$0.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Amneal Pharmaceuticals (AMRX)?

Short answer · as of

Cash and short-term investments were $157.40M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $100.28M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash position deteriorated despite operational profitability—working capital swings and heavy capex consumed what should have been strong free cash. Debt substantially exceeds available cash, placing debt service ahead of strategic investment or shareholder returns. Refinancing risk is manageable near-term but credit cost constrains margin. A ratings downgrade would be a sharp reset to competitive position.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 49.12 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$100.28M Sep 30, 2026
Previous quarter · operating cash flow
−$19.26M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$100.28M−$39.58M
Jun 30, 2026−$19.26M−$45.59M
Mar 31, 2026−$28.72M−$13.86M
Dec 31, 2025$130.32M−$43.17M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Amneal Pharmaceuticals (AMRX)?

Short answer · as of

The next earnings report is expected on Feb 26, 2027.

Watch debt covenant compliance and near-term refinancing terms as leverage climbs. Generics volume could reverse if supply recovery saturates or competitors cut prices sharply—margin compression would force infrastructure costs down. Monitor Specialty uptake against management guidance and whether AvKARE contract renewals hold steady.

What management is planning

Management's statements are quoted under Upcoming events

5 · Peer comparison

How does Amneal Pharmaceuticals compare with its peers?

Short answer

Amneal Pharmaceuticals's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Against larger generics specialists, Amneal's Specialty and government segments differentiate—but smaller scale versus integrated peers means higher financing costs and less R&D cushion. Against pure-Specialty players, it carries commodity exposure. The hybrid model avoids the margin floor of pure Generics yet lacks the pricing power of pure-play branded. It is defensible but not dominant.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Named competitor$102.10 Nov 20, 2026$6.68B96 5-pillar Nov 22, 2026
ANI Pharmaceuticals, Inc. (ANIP) Same industry, near in market value$68.55 Nov 20, 2026$1.56B94 5-pillar Nov 22, 2026
Zoetis Inc. (ZTS) Same industry, near in market value$79.11 Nov 20, 2026$32.1B87 5-pillar Nov 22, 2026
Envista Holdings Corp. (NVST) Named competitor$22.91 Nov 20, 2026$3.67B82 5-pillar Nov 22, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.89 Nov 20, 2026$12.4B79 5-pillar Nov 22, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.61 Nov 20, 2026$5.94B75 5-pillar Nov 22, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.22 Nov 20, 2026$2.39B71 5-pillar Nov 22, 2026
Amneal Pharmaceuticals (AMRX) — this page$21.12$7.36B68
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.18 Nov 20, 2026$2.07B48 5-pillar Nov 22, 2026
Telix Pharmaceuticals Limited (TLX) Named competitor$8.37 Nov 20, 2026$2.84B40 5-pillar Nov 22, 2026
Elanco Animal Health Incorporated (ELAN) Same industry, near in market value$25.74 Nov 20, 2026$12.9B36 5-pillar Nov 22, 2026
Viatris Inc. (VTRS) Same industry, near in market value$19.63 Nov 20, 2026$22.5B35 5-pillar Nov 22, 2026
Bausch Health Companies Inc. (BHC) Same industry, near in market value$8.22 Nov 20, 2026$3.08B30 5-pillar Nov 22, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$20.00 – $27.00
Consensus target
$23.43
Median target
$24.00

Consensus record · Captured .

Measured against a quoted price of $21.12 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026

Transactions
15
Identified insiders
9
Purchases
0
Sales
4
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
53.0% Period end Sep 30, 2026
Previous quarter · ownership
50.3% Prior to period end Sep 30, 2026
Reporting holders
338 Period end Sep 30, 2026
Previous quarter · holders
315 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.26,877,188
Vanguard Portfolio Management LLC12,365,663
Tpg Gp A, LLC12,328,767
Rubric Capital Management LP8,536,755
Vanguard Capital Management LLC7,987,664

Tracked investors

Which of the 16 named investors we follow held AMRX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AMRX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About AMRX (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What is AvKARE and why does Amneal own it?

AvKARE serves government buyers—DoD and Veterans Affairs—with bulk pharmaceuticals and medical supplies under long-term contracts. It is a sticky, contract-based business insulated from wholesale commodity pricing. Revenue is stable and predictable, providing portfolio diversification.

Does Amneal have blockbuster drugs?

Rytary for Parkinson's and Unithroid for thyroid disorders are established and profitable, but neither is blockbuster-scale by industry standards. They drive Specialty margins substantially above Generics but cannot offset commodity price pressures alone.

Can Amneal pay down debt from operations?

Operating cash turned negative in the most recent quarter despite earnings, due to working capital timing and elevated capex. Meaningful debt reduction would require sustained free cash generation or asset sales—neither is assured under current leverage and market conditions.

Why did earnings swing so dramatically last year?

A severe trough quarter appears driven by working capital pressure and possible one-time charges. The subsequent recovery reflects Generics volume normalization and full-period Specialty acquisition contributions. Durability remains unproven and depends on sustained volume and pricing.

What is the AMRX stock price today?

The last price recorded for Amneal Pharmaceuticals, Inc. (AMRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AMRX price target?

The analyst consensus price target for Amneal Pharmaceuticals, Inc. (AMRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 75 from Financial Modeling Prep (FMP), 1 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • 1. What is Amneal Pharmaceuticals (AMRX), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Amneal Pharmaceuticals (AMRX)?: Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Recent SEC filings
  • 3. What are the financial strengths and risks for Amneal Pharmaceuticals (AMRX)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions)
  • 4. What should you watch next at Amneal Pharmaceuticals (AMRX)?: Recent SEC filings; Next earnings report
  • 5. How does Amneal Pharmaceuticals compare with its peers?: Business description; Revenue by segment; Institutional ownership (13F)
  • FAQ: What is AvKARE and why does Amneal own it?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Does Amneal have blockbuster drugs?: Business description; Revenue by segment; Trailing twelve-month ratio set
  • FAQ: Can Amneal pay down debt from operations?: Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash against market value
  • FAQ: Why did earnings swing so dramatically last year?: Reported versus estimated, last 8 quarters; Recent SEC filings; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.